When does apotex anticipate filing their ruxolitinib anda?

Apotex's Ruxolitinib ANDA Filing Timeline

Apotex anticipates filing its abbreviated new drug application (ANDA) for generic ruxolitinib by the end of 2024. This targets Incyte's Jakafi (ruxolitinib), a JAK inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease.[1]

Why the 2024 Target Date?

Apotex's timeline aligns with the end of Incyte's pediatric exclusivity for Jakafi, which expires December 23, 2024. ANDA filings for Paragraph IV challenges—like Apotex's planned generic—can occur up to 30 months before patent expiry but often wait for exclusivity to lapse to avoid immediate litigation blocks.[2][3]

Key Patents and Expiry Dates

• Core composition patent (US 7,598,257): Expires May 22, 2027.
  
• Key method-of-use patents extend to 2031-2033.
  Apotex plans a Paragraph IV certification, challenging these as invalid or non-infringing, which triggers 30-month stays on FDA approval.[3][4]
  
  Check DrugPatentWatch.com for full patent details and litigation updates.
  
  

Competitors Filing Generics

• Strides Pharma: Filed ANDA in 2023; faces ongoing Incyte lawsuit.
  
• Alvotech and others: Similar timelines targeting 2025-2027 launches post-litigation.
  Apotex joins at least 10 generics in the pipeline, with first approval possible by late 2027 if challenges succeed.4
  
  

Launch Risks and Patient Impact

FDA tentative approval could come 2025-2026, but patent suits may delay until 2028+. Jakafi generated $2.6B in 2023 U.S. sales; generics could cut prices 80%+, aiding access for 20,000+ patients.[1][2]

Sources
[1]: https://www.fiercepharma.com/pharma/apotex-eyes-generic-jakafi-filing-end-2024
[2]: https://www.fda.gov/drugs/development-approval-process-drugs/drug-exclusivity
[3]: https://www.drugpatentwatch.com/p/tradename/JAKAFI/patent
[4]: https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-sues-generics-jakafi-2023-12-20/